Shire Development LLC et al v. Watson Pharmaceuticals, Inc. et al

  1. March 28, 2016

    Actavis' Generic Lialda Still Too Early, Judge Finds

    A Florida federal judge on Monday barred Actavis from launching its generic version of Shire’s inflammatory bowel disease treatment Lialda until the patent for the drug expires in June 2020, following a second bench trial on the matter.

  2. March 24, 2016

    Shire, Actavis Feud Over Unresolved Issues At Lialda IP Trial

    A lack of definitive rulings from the Federal Circuit on certain issues in Shire's suit over Actavis' proposed generic version of its gastrointestinal drug Lialda emerged as a major point of contention during closing arguments Wednesday in a Florida federal court, in its second bench trial on the matter.

  3. January 25, 2016

    Lialda Patent Dispute Seeks Definition In Second Trial

    A second bench trial began Monday in Florida in a patent dispute over a generic version of Shire PLC's inflammatory bowel disease treatment Lialda, with the parties offering varying views on the court's task after an appeals court rejected Shire's argument that it applied a review standard incorrectly.

  4. May 09, 2013

    Shire Blocks Actavis' Generic Lialda Until 2020

    A Florida federal judge on Thursday blocked Actavis Inc.'s bid to launch a generic version of Shire PLC's inflammatory bowel disease treatment Lialda, ruling that Shire's patent for the drug was both valid and infringed.

  5. March 25, 2013

    Watson Can't Skirt Shire's Colitis Drug Patent Suit

    A Florida federal judge on Thursday declined to rule outright that Irish drugmaker Shire Development LLC's patent for its ulcerative colitis drug Lialda was invalid, rejecting an attempt by Watson Pharmaceuticals Inc. to have the court clear the way for its generic version of the drug.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!